HBIO — HARVARD BIOSCIENCE INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on HBIO
| date | signal | measured base rate |
|---|---|---|
| 2026-07-22 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-18 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-09 | Gagnon Robert E. Director | Grant or award | 16.6K | 0.00 | 0 |
| 2026-06-09 | Eade Katherine A. Director | Grant or award | 16.6K | 0.00 | 0 |
| 2026-06-09 | Benson Seth Benjamin Director | Grant or award | 16.6K | 0.00 | 0 |
| 2026-06-09 | Snider William Director | Grant or award | 16.6K | 0.00 | 0 |
| 2026-06-09 | DENELSKY STEPHEN J Director | Grant or award | 16.6K | 0.00 | 0 |
| 2026-03-20 | Frost Mark T Chief Financial Officer | Grant or award | 30.0K | 0.00 | 0 |
| 2026-03-20 | Duke John D Chief Executive Officer | Grant or award | 75.0K | 0.00 | 0 |
| 2026-03-17 | DENELSKY STEPHEN J Director | Open-market purchase | 10.0K | 4.87 | 48.7K |
| 2026-03-17 | Snider William Director | Open-market purchase | 8.5K | 4.85 | 41.1K |
| 2026-03-16 | Snider William Director | Open-market purchase | 12.5K | 4.99 | 62.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| WEBER CAPITAL MANAGEMENT LLC /ADV | 1.6M | 320.0K |
| VANGUARD CAPITAL MANAGEMENT LLC | 795.3K | 163.3K |
| CORSAIR CAPITAL MANAGEMENT, L.P. | 607.8K | 124.8K |
| TWO SIGMA INVESTMENTS, LP | 555.8K | 114.1K |
| RENAISSANCE TECHNOLOGIES LLC | 493.9K | 101.4K |
| BlackRock, Inc. | 303.0K | 62.2K |
| GEODE CAPITAL MANAGEMENT, LLC | 289.9K | 59.5K |
| MILLENNIUM MANAGEMENT LLC | 225.6K | 46.3K |
| Williams & Novak, LLC | 137.7K | 27.1K |
| VANGUARD FIDUCIARY TRUST CO | 135.0K | 27.7K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript · 2026-08-18
- Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights - GuruFocus · 2026-08-11 · GuruFocus
- Harvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59% · 2026-08-11
- Harvard Bioscience beats top-line and bottom-line estimates; gives Q3 and raises FY2026 outlook · 2026-08-11
- Harvard Bioscience Inc (HBIO) filed form 8-K · 2026-08-11 · SEC EDGAR
- Harvard Bioscience Inc (HBIO) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about HBIO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →